Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers Nasdaq:IMMU

Press/Media: Press / Media

PeriodSep 18 2020

Media coverage

5

Media coverage

  • TitleImmunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers Nasdaq:IMMU
    Media name/outletGlobal English (Middle East and North Africa Financial Network)
    CountryJordan
    Date9/18/20
    PersonsAndrew Brenner
  • TitleEncouraging Early Stage Clinical Results with Trodelvy(TM) in Brain Cancers
    Media name/outletMarket News Publishing
    CountryUnited States
    Date9/18/20
    PersonsAndrew Brenner
  • TitleImmunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy(TM) in Brain Cancers
    Media name/outletChase
    CountryUnited States
    Date9/18/20
    PersonsAndrew Brenner
  • TitleIMMUNOMEDICS : Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers
    Media name/outletMarketScreener.com
    CountryUnited States
    Date9/18/20
    PersonsAndrew Brenner
  • TitleImmunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy„¢ in Brain Cancers; Results include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM)
    Media name/outletPrimeNewswire (Top News)
    CountryUnited States
    Date9/18/20
    PersonsAndrew Brenner